Clinical Trial

Needs of ALS Patients With C9orf72 Mutation and Their Caregivers

Study acronym: C9survALS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 4, 2026 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
Individuals with Amyotrophic Lateral Sclerosis (ALS) carrying the C9orf72 HRE mutation (C9Pos) often exhibit different phenotypic traits compared to other patients (C9Neg), presenting a more aggressive form of the disease, with also a higher frequency of comorbidity with frontotemporal dementia (ALS-FTD) and a greater prevalence of family history of ALS and/or other neurodegenerative diseases. Considering these characteristics (comorbidity with FTD and family history of ALS and/or other neurodegenerative pathologies) as factors that have their importance from an assistance point of view, both C9orf72 patients and their caregivers may have particular needs in several respects, and in this sense this investigation is configured. This survey aims to describe the various aspects related to the care and quality of life of C9orf72 ALS patients and their respective caregivers, with the goal of identifying actionable steps to improve the quality of life for both.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-10.
Trial Details
NCT Number NCT07302321
Lead Sponsor Istituto Auxologico Italiano
Conditions Amyotrophic Lateral Sclerosis
Enrollment 208 participants
Start Date 2025-10-01
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-04